Eiry W. Roberts, M.D., serves as the Chief Medical Officer at Neurocrine Biosciences Inc., a biopharmaceutical company focused on developing treatments for neurological and endocrine-related diseases. Dr. Roberts has been a pivotal figure in the company since joining in 2018, bringing a wealth of experience and expertise in clinical development and medical affairs. With a medical degree from the University of Oxford, Dr. Roberts has dedicated their career to advancing patient care through innovative drug development. Prior to their role at Neurocrine Biosciences, Dr. Roberts held several key positions in the pharmaceutical industry. They served as the Vice President of Clinical Development at Amgen, where they were instrumental in the development and approval of several blockbuster drugs. Dr. Roberts also worked at Genentech, contributing to the clinical development of oncology treatments that have significantly improved patient outcomes. Their extensive background in both neurology and oncology has equipped them with a unique perspective on the challenges and opportunities within the biopharmaceutical sector. As Chief Medical Officer at Neurocrine Biosciences, Dr. Roberts oversees the company's clinical development strategy and medical affairs, guiding the organization through the complex process of bringing new therapies to market. Under their leadership, Neurocrine has made significant strides in developing treatments for conditions such as Parkinson's disease, epilepsy, and endometriosis. Dr. Roberts is also committed to fostering a culture of innovation and collaboration within the company, ensuring that Neurocrine remains at the forefront of scientific advancement in the field of neurology and endocrinology.